DRTS on Nasdaq
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. is a surgical and medical instruments and apparatus company, listed on Nasdaq (DRTS).1
Price unavailable
Last updated Oct 21, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development, net | $32.1M | $27.0M | $26.4M |
| Marketing expenses | $1.9M | $2.3M | $1.9M |
| General and administrative | $8.4M | $6.7M | $7.3M |
| Total operating loss | $42.3M | $36.0M | $35.7M |
| Financial (income) expenses, net | $218.0K | -$4.3M | -$6.5M |
| Loss before taxes on income | $42.5M | $31.7M | $29.1M |
| Tax on income | $121.0K | $6.0K | $16.0K |
| Net loss | $42.6M | $31.8M | $29.2M |
| Net comprehensive loss | $42.6M | $31.8M | $29.2M |
| Net loss per share, basic (in Dollars per share) | -$0.53 | -$0.45 | -$0.42 |
| Net loss per share, diluted (in Dollars per share) | -$0.53 | -$0.45 | -$0.42 |
| Weighted-average shares used in computing net loss per share, basic (in Shares) | 80.6M shares | 69.9M shares | 69.4M shares |
| Weighted-average shares used in computing net loss per share, diluted (in Shares) | 80.6M shares | 69.9M shares | 69.4M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $12.2M | $13.7M | ||
| Short-term deposits | $60.9M | $45.9M | ||
| Restricted deposits | $3.8M | $3.3M | ||
| Prepaid expenses and other receivables | $1.4M | $1.4M | ||
| Total current assets | $78.3M | $64.2M | ||
| Long-term prepaid expenses | $479.0K | $432.0K | ||
| Property and equipment, net | $19.7M | $13.9M | ||
| Operating lease right-of-use assets | $7.2M | $7.6M | ||
| Total long-term assets | $27.4M | $22.0M | ||
| Total assets | $105.7M | $86.2M | ||
| Trade payables | $3.9M | $3.5M | ||
| Other payables and accrued expenses | $5.5M | $4.1M | ||
| Current maturities of operating lease liabilities | $1.1M | $1.0M | ||
| Total current liabilities | $10.5M | $8.7M | ||
| Long-term loan | $6.4M | $5.6M | ||
| Warrants liability | $5.4M | $3.3M | ||
| Operating lease liabilities | $6.2M | $6.0M | ||
| Deferred tax liability | $97.0K | |||
| Total long-term liabilities | $18.0M | $14.9M | ||
| Total liabilities | $28.6M | $23.5M | ||
| Additional paid-in capital | $267.2M | $210.2M | ||
| Accumulated deficit | -$190.1M | -$147.5M | ||
| Total shareholders equity | $77.1M | $62.7M | $84.5M | $105.7M |
| Total liabilities and shareholders equity | $105.7M | $86.2M | ||
| Ordinary shares, authorized (in Shares) | 362.1M shares | 362.1M shares | ||
| Ordinary shares, issued (in Shares) | 88.0M shares | 70.4M shares | ||
| Ordinary shares, outstanding (in Shares) | 88.0M shares | 70.4M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $12.2M | $13.7M | ||
| Short-term deposits | $60.9M | $45.9M | ||
| Restricted deposits | $3.8M | $3.3M | ||
| Prepaid expenses and other receivables | $1.4M | $1.4M | ||
| Total current assets | $78.3M | $64.2M | ||
| Long-term prepaid expenses | $479.0K | $432.0K | ||
| Property and equipment, net | $19.7M | $13.9M | ||
| Operating lease right-of-use assets | $7.2M | $7.6M | ||
| Total long-term assets | $27.4M | $22.0M | ||
| Total assets | $105.7M | $86.2M | ||
| Trade payables | $3.9M | $3.5M | ||
| Other payables and accrued expenses | $5.5M | $4.1M | ||
| Current maturities of operating lease liabilities | $1.1M | $1.0M | ||
| Total current liabilities | $10.5M | $8.7M | ||
| Long-term loan | $6.4M | $5.6M | ||
| Warrants liability | $5.4M | $3.3M | ||
| Operating lease liabilities | $6.2M | $6.0M | ||
| Deferred tax liability | $97.0K | |||
| Total long-term liabilities | $18.0M | $14.9M | ||
| Total liabilities | $28.6M | $23.5M | ||
| Additional paid-in capital | $267.2M | $210.2M | ||
| Accumulated deficit | -$190.1M | -$147.5M | ||
| Total shareholders equity | $77.1M | $62.7M | $84.5M | $105.7M |
| Total liabilities and shareholders equity | $105.7M | $86.2M | ||
| Ordinary shares, authorized (in Shares) | 362.1M shares | 362.1M shares | ||
| Ordinary shares, issued (in Shares) | 88.0M shares | 70.4M shares | ||
| Ordinary shares, outstanding (in Shares) | 88.0M shares | 70.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$42.6M | -$31.8M | -$29.2M |
| Depreciation | $1.2M | $1.1M | $1.1M |
| Loss from property and equipment disposals | $35.0K | ||
| Share-based compensation | $10.6M | $9.9M | $7.9M |
| Non-cash financial expenses (income), net | -$245.0K | $40.0K | $1.7M |
| Decrease (increase) in prepaid expenses and other receivables | -$21.0K | -$558.0K | $281.0K |
| (Increase) decrease in long-term prepaid expenses | -$47.0K | $39.0K | -$80.0K |
| Change in the fair value of warrants liabilities | $2.0M | -$259.0K | -$2.0M |
| Increase in trade payables | $337.0K | $965.0K | $1.1M |
| Increase in other payables and accrued expenses | $1.1M | $659.0K | $1.2M |
| Increase in deferred taxes liability | $97.0K | ||
| Change in operating lease liabilities | -$23.0K | -$726.0K | -$809.0K |
| Change in operating lease right-of-use assets | $817.0K | $789.0K | $729.0K |
| Net cash used in operating activities | -$26.7M | -$19.8M | -$18.0M |
| Investment in short-term deposits | -$70.5M | -$125.1M | -$163.6M |
| Investment in restricted deposit | -$103.0K | -$3.2M | |
| Proceeds from short-term deposits | $56.0M | $148.2M | $191.9M |
| Purchase of property and equipment | -$6.1M | -$2.2M | -$6.4M |
| Net cash provided by (used in) investing activities | -$20.6M | $20.8M | $18.7M |
| Proceed from short-term loan | $5.2M | ||
| Repayment of short-term loan | -$5.2M | ||
| Proceeds from long-term loan | $5.2M | ||
| Proceeds from issuance of Ordinary shares, net | $45.5M | ||
| Proceeds from exercise of options | $272.0K | $25.0K | $49.0K |
| Net cash provided by financing activities | $45.8M | $25.0K | $5.3M |
| Effect of exchange rate changes on cash and cash equivalents | -$21.0K | $57.0K | -$50.0K |
| Increase (decrease) in cash and cash equivalents | -$1.5M | $1.1M | $6.0M |
| Income taxes paid | $4.0K | $5.0K | $16.0K |
| Interest received | $2.8M | $4.4M | $6.2M |
| Interest paid | $381.0K | $321.0K | $52.0K |
| Operating lease liabilities arising from obtaining right of use assets | $422.0K | $35.0K | $3.3M |
| Purchases of property and equipment in exchange for Ordinary shares | $675.0K | ||
| Purchases of property and equipment in other payables and accrued expenses | $244.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Alpha Tau Medical Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Alpha Tau Medical Ltd.
- Uzi Sofer Filed SCHEDULE 13G on Alpha Tau Medical Ltd., latest Jul 24, 2025
- Oramed Pharmaceuticals Filed SCHEDULE 13D on Alpha Tau Medical Ltd., latest May 1, 2025
- Alpha Tau Medical Ltd. L3
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Alpha Tau Medical Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $24.9M2 Dec 31, 2025 | $18.0M2 Dec 31, 2024 | +38.6% |
| Accumulated depreciation | $5.3M2 Dec 31, 2025 | $4.1M2 Dec 31, 2024 | +30.1% |
| Property and equipment, net | $19.7M2 Dec 31, 2025 | $13.9M2 Dec 31, 2024 | +41.1% |
| Operating-lease assets (leased space) | $7.2M2 Dec 31, 2025 | $7.6M2 Dec 31, 2024 | −5.2% |
Investments
Leadership
Who has led Alpha Tau Medical Ltd., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerUzi Sofer Mar 18, 2026 to now8
- Chief financial officerRaphi Levy Mar 18, 2026 to now9
Board members and other officers (8)
- Board memberAlan Adler Mar 18, 2026 to now10
- Board memberDavid Mark Milch Mar 18, 2026 to now11
- Board memberMaya Netser Mar 18, 2026 to now12
- Board memberMichael Avruch Mar 18, 2026 to now13
- Board memberNadav Kidron Mar 18, 2026 to now14
- Board memberRuth Alon Mar 18, 2026 to now15
- Board memberS. Morry Blumenfeld Mar 18, 2026 to now16
- Board memberUzi Sofer Mar 18, 2026 to now8
Timeline
- Mar 18, 2026New chief executive Uzi Sofer becomes CEO8
Calendar
Coming up
- Nov 19, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.14) a share, on Nov 20, 2025.17
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
232 filings to the SEC since October 2021: 6 annual reports, 18 insider forms, 2 large holders, 206 other. The latest 20:
- Aug 31, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 25, 20264 PRIMARY DOCUMENT EDGAR
- Aug 21, 2026144 EDGAR
- Aug 12, 20264 PRIMARY DOCUMENT EDGAR
- Aug 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 21, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 7, 20264 PRIMARY DOCUMENT EDGAR
- Jul 6, 2026144 EDGAR
- Jul 6, 20264 PRIMARY DOCUMENT EDGAR
- Jul 2, 2026144 EDGAR
- Jul 2, 20264 PRIMARY DOCUMENT EDGAR
- Jul 1, 20264 PRIMARY DOCUMENT EDGAR
- Jun 30, 2026144 EDGAR
- Jun 26, 2026144 EDGAR
- Jun 26, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 23, 2026144 EDGAR
The 232 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
9 open-market trades by officers, directors and large owners since October 2021: 0 buys and 9 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Levy RaphiChief Financial Officer | Sale | 2,871 | $15.00 | $43.1K | Form 4 |
| Aug 11, 2026 | Levy RaphiChief Financial Officer | Sale | 17,730 | $14.00 | $248.2K | Form 4 |
| Jul 6, 2026 | Levy RaphiChief Financial Officer | Sale | 2,270 | $14.00 | $31.8K | Form 4 |
| Jul 2, 2026 | Levy RaphiChief Financial Officer | Sale | 17,873 | $13.00 | $232.3K | Form 4 |
| Jul 1, 2026 | Levy RaphiChief Financial Officer | Sale | 2,127 | $13.02 | $27.7K | Form 4 |
| Jun 30, 2026 | Levy RaphiChief Financial Officer | Sale | 20,000 | $12.00 | $240.0K | Form 4 |
| Jun 25, 2026 | Levy RaphiChief Financial Officer | Sale | 20,000 | $11.00 | $220.0K | Form 4 |
| Jun 23, 2026 | Levy RaphiChief Financial Officer | Sale | 17,500 | $9.55 | $167.1K | Form 4 |
| Jun 3, 2026 | Levy RaphiChief Financial Officer | Sale | 32,500 | $10.84 | $352.1K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Uzi SoferSCHEDULE 13G, 1 filing Jul 24, 202518
- Oramed PharmaceuticalsSCHEDULE 13D, 1 filing May 1, 202519
SEC filer profile
How Alpha Tau Medical Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAlpha Tau Medical Ltd.1
- CIK0001871321
- Filer statusAccelerated filer an emerging growth company; not a shell company20
- Incorporated inIsrael20
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business addressKiryat Hamada 5, Jerusalem, L3 97776051
- Phone972-3-577-41151
- Shares outstanding88,009,737 shares as of Dec 31, 202520
- AuditorKOST FORER GABBAY & KASIERER, Tel-Aviv, Israel PCAOB ID 1281; no auditor attestation of internal control over financial reporting20
- On EDGAR sinceJul 8, 20211
- Filings236 in all: 6-K (121), 144 (24), CORRESP (11), 3 (9), 4 (9), 425 (9), UPLOAD (9), EFFECT (8)1
All 23 form types
424B3 (7), 20-F (5), S-8 (5), F-3 (4), F-4/A (4), POS AM (2), 20-F/A (1), 424B5 (1), 8-A12B (1), CERT (1), F-1 (1), F-1/A (1), F-4 (1), SCHEDULE 13D (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (20-F) Mar 9, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary shares, no par value | DRTS | Nasdaq |
| Warrants to purchase ordinary shares | DRTSW | Nasdaq |
From the cover page of the 20-F filed Mar 9, 2026 (Section 12(b) of the Exchange Act).20
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8SEC EDGARUzi Sofer, Chief executive officer
- 9SEC EDGARRaphi Levy, Chief financial officer
- 10SEC EDGARAlan Adler, Board member
- 11SEC EDGARDavid Mark Milch, Board member
- 12SEC EDGARMaya Netser, Board member
- 13SEC EDGARMichael Avruch, Board member
- 14SEC EDGARNadav Kidron, Board member
- 15SEC EDGARRuth Alon, Board member
- 16SEC EDGARS. Morry Blumenfeld, Board member
- 17NasdaqNasdaq calendar
- 18
- 19
- 20